renin-angiotensin-aldosterone system (RAAS)

Theasinensin C is an orally active renin inhibitor with an IC50 of 40.21 μM, demonstrating significant modulation of gut microbiota. It selectively enhances the population of Akkermansia muciniphila, promoting beneficial hydrolysis of mucin and influencing the gut-kidney-liver metabolic signaling pathways that contribute to creatine biosynthesis. This compound is valuable for studying hypertension and neuroinflammation, especially in the context of high-fructose diets, as it has been shown to improve cognitive function, reduce pro-inflammatory cytokines, and restore intestinal barrier integrity.

PD 132002 is a potent, orally active inhibitor of renin, a key enzyme in the renin-angiotensin system. By effectively reducing plasma renin activity, PD 132002 leads to significant decreases in blood pressure. This compound serves as a valuable tool for research into hypertension and related cardiovascular disorders. Additionally, it exhibits weak inhibition of pepsin, highlighting its specific targeting mechanism.

CP 71362 is a potent renin inhibitor that acts as a substrate-analog transition state mimic, demonstrating significant antihypertensive activity. It effectively inhibits plasma renin across species, with IC50 values of 3 nM in rats, 0.0033 nM in dogs, and 20 nM in humans. CP 71362 significantly reduces mean arterial pressure in both anesthetized and conscious sodium-depleted models, showing a dose-dependent effect. This compound is valuable for research focused on hypertension and congestive heart failure.

A-74273 is an orally active peptide renin inhibitor with an IC50 value of 3.1 nM. This compound competitively inhibits renin by binding to its active site, thereby obstructing the conversion of angiotensinogen to angiotensin I and subsequently reducing angiotensin II levels. A-74273 is utilized in research focused on hypertension and related cardiovascular diseases.

Renin inhibitor-1 is a potent, orally active renin inhibitor with IC50 values of 0.9 nM for recombinant human renin and 1.8 nM for human plasma renin activity (hPRA). This compound demonstrates significant antihypertensive efficacy, making it a valuable tool for studying hypertension and related cardiovascular and renal diseases. Its ability to effectively inhibit renin positions it as a key agent in cardiovascular research.

PD 125967 is an oligopeptide renin inhibitor that specifically targets the renin-angiotensin system. It exhibits significant activity in lowering blood pressure, making it a valuable tool for cardiovascular research. This compound is useful for studying hypertension and related disorders, providing insights into the regulation of blood pressure through renin inhibition.

Remikiren is a potent and selective inhibitor of renin, demonstrating high specificity with IC50 values of 0.7 nM for human renin and 0.8 nM for human plasma renin. This compound effectively lowers mean arterial blood pressure in sodium-depleted marmosets and squirrel monkeys, making it a valuable tool for research into hypertension. Remikiren serves as a key reagent for exploring the renin-angiotensin system and its implications in cardiovascular diseases.

SR 43845 is a selective renin inhibitor that effectively reduces blood pressure by inhibiting plasma renin activity. This compound is primarily used in hypertension research, providing valuable insights into the regulation of blood pressure and the renin-angiotensin system. Its application in preclinical studies can aid in the development of therapeutic strategies for hypertension management.

PD-134672 is a potent renin inhibitor featuring a 2-amino-4-thiazolyl substituent. It demonstrates significant in vitro inhibition of monkey renin, while exhibiting only minimal effects on the related protease bovine feline hepsin D. This compound has shown oral hypotensive activity in hyperreninemic normotensive monkeys and has been identified for further evaluation in renal hypertensive models due to its strong efficacy and prolonged effects. PD-134672 is a valuable tool for research exploring mechanisms of hypertension and the therapeutic potential of renin inhibition.

EMD 52297 is a potent renin inhibitor that effectively modulates hemodynamic and hormonal responses. In addition to its primary action, EMD 52297 also exhibits activity as an angiotensin-converting enzyme (ACE) inhibitor. This compound is primarily utilized in cardiovascular research and hypertension studies, providing insights into the regulation of blood pressure and renal function.

A-65317 is a primate-selective renin inhibitor that exhibits a potent inhibitory effect with an IC50 of 0.37 nM. This compound is known for its long-lasting hypotensive response, making it valuable in cardiovascular research. A-65317 can be utilized in studies focused on hypertension and renal function regulation.

Cgp 38560 methanesulfonate is a selective renin inhibitor that modulates the renin-angiotensin system. This compound exhibits a dose-dependent decrease in angiotensin II levels and plasma renin activity, while simultaneously increasing active renin concentrations. Cgp 38560 methanesulfonate is utilized in research focused on hypertension and cardiovascular disease, providing valuable insight into renin regulation and therapeutic interventions.

PD125754 is a potent oligopeptide inhibitor of renin, exhibiting an IC50 of 22 nM. This compound effectively reduces renin activity, making it valuable for studies related to hypertension and cardiovascular diseases. Its ability to modulate the renin-angiotensin system can aid in the exploration of mechanisms underlying renal and cardiovascular function.

SC-46944 is an orally active renin inhibitor that effectively targets the renin-angiotensin system. It demonstrates significant potential in the study of hypertension by reducing renin activity and subsequently lowering blood pressure. This compound serves as a valuable tool in cardiovascular research and the development of antihypertensive therapies.

ES 6864 is a potent, orally active competitive inhibitor of human renin, demonstrating an IC50 of 6.9 nM and a Ki of 7.3 nM. It possesses high specificity for both species and enzyme, making it a valuable tool in cardiovascular research. Additionally, ES 6864 exhibits metabolic stability in rat tissue homogenates and effectively lowers blood pressure in rat models and sodium-depleted awake marmosets, supporting its potential applications in hypertension studies.

ACT 178882 is a potent renin inhibitor with an IC50 of 1.4 nM. It effectively modulates the renin-angiotensin-aldosterone system, leading to potential applications in the treatment of hypertension and related cardiovascular disorders. This compound serves as a valuable tool for research into the role of renin in blood pressure regulation and the development of novel antihypertensive therapies.